Leadership Team


Dr John Ford, Chief Executive Officer

Dr John Ford, Chief Executive Officer

Dr John Ford has more than 18 years of ion channel, drug discovery and development experience. As a successful biotechnology entrepreneur he co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (co-owner). At Xention he was responsible for the Kv1.5 ion channel atrial fibrillation project which was partnered to Servier (up to 120M EUR). Recently, he was a member of the Executive Team at Dezima (COO) that developed TA-8995 for dyslipidaemia (Phase 2b study published in The Lancet) and sold the company to Amgen ($300M upfront, potential deal size of US$1.55bn + royalties). Previous positions include Team Leader for Receptors and Channel Drug Discovery at BioFocus (now owned by Charles River). Dr Ford holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

Prof Martin Gosling, Chief Scientific Officer

Prof Martin Gosling, Chief Scientific Officer

Prof Martin Gosling has spent his research career exploiting the therapeutic potential of ion channels in both industrial and academic settings. Prior to co-founding Enterprise Therapeutics, Prof Gosling was Executive Director in the Respiratory Disease Area of the Novartis Institutes for BioMedical Reseach, UK. Whilst with Novartis he established an internal ion channel platform, was a successful Project Team Leader for multiple drug discovery programs and played a lead role in defining the Novartis cystic fibrosis (CF) portfolio. Prof Gosling holds a BSc and PhD in Pharmacology from the Universities of Leeds and Aston respectively. In addition to his position as CSO of Enterprise Therapeutics, he also holds the position of Professor of Molecular Pharmacology at the University of Sussex.

Dr Stephen Collingwood, Head of Chemistry

Dr Stephen Collingwood, Head of Chemistry

Steve obtained his first degree in chemistry from the University of Durham and his PhD in organic chemistry from the University of Newcastle. After postdoctoral research at the University of Oxford, he joined the central research laboratories of Ciba Geigy, which later became Novartis. In 1997 he joined the Novartis respiratory disease team. During his time there, he led the chemistry on multiple respiratory projects, delivering several clinical candidates and contributing to two successful human proof of concept studies. In 2006 his contributions were recognised with a Novartis Leading Scientist award. He later became Director of Respiratory Medicinal Chemistry and a member of the Novartis Respiratory Disease Area Board. In 2014 he joined Janssen as Head of Chemistry for the respiratory research activities at its Respivert subsidiary, where he led a new research project and oversaw the inhaled DMPK strategy and Respivert IP portfolio. Throughout his time in respiratory research Steve has a particular interest in the design of novel inhaled medicines. He is an author of over 70 patents and publications.

Dr Henry Danahay, Head of Biology

Dr Henry Danahay, Head of Biology

Dr Henry Danahay gained a BPharm and PhD from the Welsh School of Pharmacy before joining the Novartis Respiratory Diseases Group. Whilst with Novartis, he worked as an in vitro/in vivo pharmacologist with a specialisation in airway epithelial cell based drug targets. During this time he played a central role in establishing the CF discovery portfolio and was most recently Director and Head of the Lung Repair & Regeneration Group in the Respiratory Disease Area. He has lead a number of drug discovery programs from target identification through to early clinical studies as well as authoring >40 peer reviewed papers and patents. As a co-founder of Enterprise Therapeutics, Dr Danahay is Head of Biology and is an honorary Senior Research Fellow at the University of Sussex.

Dr Phil Boyd,  Chief Financial Officer

Dr Phil Boyd, Chief Financial Officer

Dr Phil Boyd was CFO of Syntaxin Ltd from 2007 through to the acquisition by Ipsen in July 2013, and CFO of Tiziana Lifesciences plc (AIM: TILS) from 2014 to 2015. Prior to Syntaxin he was UK Finance Director of Evotec AG (2001-2007) and Cambridge Discovery Chemistry (1999-2001). He currently serves as CFO with Enterprise Therapeutics and Oxford BioDynamics, and as a Non-Executive Director with OBN (UK) Ltd. He has a BSc in Biotechnology and a PhD in Genetics from University of Leeds, and is a qualified management accountant (ACMA).

Paul Russell, Project Director (Development)

Paul Russell, Project Director (Development)

Paul has more than 20 years’ experience in the pharma and biotech industry. Prior to joining Enterprise Therapeutics, he was Director of Early Clinical Development and Project Leader for RespiVert,, successfully leading both pre-clinical and clinical programs. Paul’s respiratory expertise was developed at GSK where he was more latterly Therapy Area Director for the Clinical Pharmacology Science and Operations team, leading a group delivering early clinical programs across the respiratory portfolio. Experience in late phase clinical development was also gained at companies including Servier and AstraZeneca.